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Myxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation. Although
tumors are initially radio- and chemosensitive, the management of inoperable or metastatic MLS can be
challenging. Therefore, our aim was to identify novel targets for systemic therapy. We performed an in vitro high-
throughput drug screen using three MLS cell lines (402091, 1765092, DL-221), which were treated with 273
different drugs at four different concentrations. Cell lines and tissue microarrays were used for validation. As
expected, all cell lines revealed a strong growth inhibition to conventional chemotherapeutic agents, such as
anthracyclines and taxanes. A good response was observed to compounds interfering with Src and the mTOR
pathway, which are known to be affected in these tumors. Moreover, BIRC5 was important for MLS survival
because a strong inhibitory effect was seen at low concentration using the survivin inhibitor YM155, and siRNA for
BIRC5 decreased cell viability. Immunohistochemistry revealed abundant expression of survivin restricted to the
nucleus in all 32 tested primary tumor specimens. Inhibition of survivin in 402-91 and 1765-92 by YM155 increased
the percentage S-phase but did not induce apoptosis, which warrants further investigation before application in
the treatment of metastatic MLS. Thus, using a 273-compound drug screen, we confirmed previously identified
targets (mTOR, Src) in MLS and demonstrate survivin as essential for MLS survival.
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Myxoid liposarcoma (MLS) is a malignant soft tissue tumor
accounting for 20% to 30% of the liposarcomas and roughly 5%
of all soft tissue sarcomas [1]. These tumors are histopathologically
characterized by a proliferation of stellate spindle cells with
monomorphic ovoid nuclei, embedded in a myxoid matrix with a
plexiform vasculature [1]. High-grade tumors are defined by having
more than 5% of closely packed small blue round cells with high
nuclear/cytoplasm ratio and scant stroma. MLS is genetically
characterized by a reciprocal translocation t(12;16)(q13;p11),
generating a fusion product of FUS and DDIT3. The chimeric
fusion oncoprotein acts as an aberrant transcription factor and is
known to influence the expression of several genes, including
inhibition of adipogenic transcription factors C/EBPα and PPARγ
[2,3].
MLS tumors are initially sensitive to conventional chemo- and
radiation therapy, but despite adequate local treatment, up to 40%
can progress to local or distant relapse [4–7]. MLS exhibits a unique
metastatic pattern, as tumor cells tend to spread to other soft tissue
sites before metastasizing to the lungs. The disease can become quite
extensive, and management of metastatic or otherwise inoperable
tumors often is challenging. This is reflected by the variable 5-year
survival rates reported in several studies, which range from 8% for
advanced disease to around 83% to 93% for cases with purely myxoid
and localized tumors [5–9].
In addition to doxorubicin and ifosfamide, recently, eribulin, a
microtubule-dynamics inhibitor, was shown to offer a survival benefit
when compared with dacarbazine in the third-line setting in
liposarcomas and is now FDA approved [10]. Moreover, MLS was
shown to be sensitive to trabectedin (ET-743, Ecteinascidin), a
natural alkylating agent derived from a marine tunicate [11]. The
drug has a complex mechanism of action that is not entirely
elucidated but involves binding to the DNA-minor groove,
interaction with DNA repair complexes, and additional effects on
the tumor microenvironment [12]. Unfortunately, similar to other
systemic therapies, resistance develops, and the antitumor effect of
trabectedin has been shown to diminish after some time on treatment
[13]. Therefore, new therapeutic approaches are warranted to
improve the outcome of advanced or metastatic MLS.
Over the past decades, therapeutic progress has been hampered by
the sparse availability of representative preclinical models. For many
years, only two published cell lines (403-91 and 1765-92) were
widely available, both of which were SV40 immortalized [14,15].
Recently, we reported on the generation of a novel MLS cell line
(DL-221) and ancillary mouse xenograft model [16]. This newly
established cell line is so far the only known MLS cell line that
underwent spontaneous immortalization.
Here we used all three available MLS cell lines in an in vitro
high-throughput drug screen to search for novel therapeutic
agents that have the potential to enter future clinical trials. Drug
screens are regularly used and contribute to the discovery of new
candidate targets in cancer therapies [17,18]; furthermore, the
pathways targeted by effective drugs can yield insights into tumor
biology. In addition to the conventional chemotherapeutic agents
used in daily practice, such as anthracyclines and taxanes, we
found that YM155, a survivin inhibitor, also strongly decreased
tumor growth. Strong nuclear accumulation of survivin was
observed in 100% of MLSs and confirmed to be essential for
tumor growth.Materials and Methods
Cell Culture
The MLS cell lines 402-91 and 1765-92 (generated using SV40
transformation and kindly provided by Pierre Åman, Sahlgrenska
Cancer Centre, Department of Pathology, Institute of Biomedicine,
University of Gothenburg, Sweden) were cultured in RPMI
supplemented with 10% fetal bovine serum (Fisher Scientific,
Landsmeer, the Netherlands) and 1% penicillin-streptomycin (100
U/ml). DL-221 was cultured with Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. All included cell lines have been well
characterized for possible alterations in MLSs. All three cell lines
are PIK3CA wild type, 402-91 and 1765-92 are TP53 wild type, and
only DL-221 has two TP53 mutations (T125R and N239D) [16].
Cells were maintained in a humidified 5% CO2 incubator at 37°C.
Cell lines were tested on a regular basis for mycoplasma infections.
Short tandem repeat typing was performed before and after the
experiments to confirm cell line identity using the Cell ID GenePrint
10 system (Promega, Leiden, the Netherlands).
Drug Screen
A high-throughput drug screen was performed in which a selection
of 273 drugs (Supplementary Table 1) out of 2100 of the Bioactive
Compound Library L1700 (Selleckchem, Houston, TX) was tested
on the three MLS cell lines. Selection was based on potential clinical
relevance of drugs. Drug stocks were dissolved in DMSO and stored
in aliquots at −80°C. Cells were seeded in 96-well plates 24 hours
before treatment. Addition of the drugs was performed with the
Freedom EVO 200 liquid handling platform (Tecan, Männedorf,
Switzerland), and final treatment concentrations were 1, 10, 100, and
1000 nM, each in triplicate. Cells were treated for 72 hours, and
thereafter, CellTiter-Blue Cell Viability Assay (#G8081, Promega,
Madison, WI) was added and incubated for 3 or 4 hours. Plates were
read at room temperature using Fluoroskan Ascent FL fluorometer
(Thermo Fisher Scientific Inc., Pittsburgh, PA), measuring the
fluorescence at 530 Ex/604 Em. Data were analyzed by Tableau
(Tableau, Seattle, WA). A compound was considered effective if able
to reduce the cell viability N50% at a drug concentration of 100 nM
in at least two cell lines.
Compounds and Cell Viability Assays
For single-agent validation studies, the survivin suppressant
YM155, sepantronium bromide (S1130, Selleckchem), everolimus
(S1120, Selleckchem), panobinostat (LBH-589, 13280, Cayman
Chemical, Ann Arbor, MI), and trabectedin (ET-743, PharmaMar,
Madrid, Spain) were dissolved in DMSO according to the
manufacturers' instructions. Z-vad-FMK (550377, BD bioscience)
was used as a general caspase inhibitor and also dissolved in DMSO.
MLS cell lines were plated in 96-well plates 24 hours before
treatment. Cells were treated with YM155 using concentrations from
0.01 until 5000 nM, in 11 steps, for 72 hours. Cell viability
experiments were performed three times, in triplicate. As MLSs are
known to respond well to trabectedin, combination treatments with
YM155 were performed to investigate possible synergism or
antagonism of both drugs. Concentrations used for combination
treatment were for both drugs selected around the IC25, IC50, and
IC75 values of single drug treatment for each cell line. This resulted in
nine different dose combinations per cell line, and drugs were added
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(Life-Technologies, Scotland, UK) was performed. Fluorescence was
measured at 590 nm on a fluorometer (Victor3V 1420 multilabel
reader, Perkin Elmer, the Netherlands). Combination experiments
were performed twice, in triplicate. To evaluate whether the
combination treatments were synergistic, a simplified version of the
Bliss independence model was applied in which the Bliss expectation
was calculated with the equation (A + B) − A × B, in which A and B
are the fractional growth inhibitions caused by compounds A and B at
a given dose, respectively [19].
siRNA Knockdown
For siRNA knockdown experiments, validated SMARTpool
siRNAs targeting BIRC5 and control siRNAs (siGAPDH and
siPLK1) were purchased from Dharmacon (GE Life Sciences,
Landsmeer, the Netherlands). For the BIRC5 SMARTpool siRNA,
we previously showed that results of the four individual siRNAs were
identical to the SMARTpool [20]. Reversed siRNA (50 nM)
transfection was carried out using DharmaFECT3 transfection
reagent (Thermo Fisher Scientific Inc.) in triplo using 5000 to
10,000 cells/well; the experiments were performed twice. After 72
hours, Presto blue assay and protein analysis by Western blot analysis
were performed.
Immunohistochemistry
Survivin expression was investigated in MLS tissue samples using a
previously constructed tissue microarray with tumor samples from 32
patients diagnosed in the Leiden University Medical Center [21]. The
tumors of 15 patients consisted of a purely myxoid (M), intermediate
cell density (I), or round cell (RC) morphology. The other 17 patients
had tumors containing a combination of two histological areas (M + I,
M + RC, or I + RC); in these cases, both areas were included, resulting
in a total of 49 tumor samples. All samples were handled in a coded
fashion, and all procedures were performed according to the ethical
guidelines, “Code for Proper Secondary Use of Human Tissue in the
Netherlands” (Dutch Federation of Medical Scientific Societies). Cell
pellets of the three untreated MLS cell lines were fixed in formalin
and embedded in paraffin by using Shandon Cytoblock (Thermo
Fisher Scientific Inc.). Sections were incubated with rabbit
anti-survivin monoclonal antibody (71G4B7, #2808; Cell Signal-
ing Technology, Leiden, the Netherlands) in a 1:100 dilution.
Staining was visualized with DAB+ substrate Chromogen System
(DAKO, Heverlee, Belgium). Placenta tissue was included as a
control. Both nuclear and cytoplasmic expression was scored
separately by two independent observers (J.V.M.G.B., M.A.G.). A
semiquantitative scoring system was used, combining the staining
intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong) and the
percentage of positive tumor cells (0 = 0%, 1 = 1%-25%, 2 =
25%-50%, 3 = 51%-75%, and 4 = 76%-100%) as described
previously [22].
RNA Isolation and Quantitative Real-Time Polymerase Chain
Reaction (PCR)
RNA was isolated from MLS cell lines using TRIzol (Invitrogen,
Carlsbad, CA) followed by a purification procedure using the RNeasy
mini kit (Qiagen, Venlo, the Netherlands) according to manufac-
turer's instructions. Quantitative PCR was performed for the isoforms
wild-type (WT) survivin, survivin 2b, and survivin Δex3 with primers
described previously [23]. Expression levels were normalized towardshousekeeping genes HPRT, GAPDH, and TBP. Results are depicted
relative to survivin WT expression for each cell line.
Apoptosis
Induction of apoptosis was assessed using the Caspase-Glo 3/7
assay (Promega, Madison, WI) according to the manufacturer's
instructions. Briefly, MLS cells were plated into white-walled 96-well
plates (Corning, Fisher Scientific, Landsmeer, the Netherlands) and
incubated with YM155 at the IC75 concentrations, as determined by
cell viability assays. After 24-hour treatment, the substrate was added
in a 1:1 dilution and incubated for 30 minutes at room temperature.
Luminescence was measured with a luminometer (Victor3V 1420
multilabel reader). Experiments were performed twice.
Western Blot
After 24 hours YM155 treated and untreated MLS cells or 72
hours after siRNA transfection MLS cells were collected in hot-SDS
buffer (1% SDS, 10 mM Tris/EDTA with complete inhibitor and
phosSTOP) for protein analysis as described previously [24]. Briefly,
5 μg or 10 μg of protein of each sample was size-fractioned on 12%
(TGX Stain-Fast Cast Acrylamide kit, BIO-RAD Laboratories)
separating gels. Jurkat cell lysate treated with 25 μM etoposide [Cell
Signaling (#2043)] was used as positive control for PARP and
cleaved PARP detection. Proteins were transferred to a PVDF
membrane and incubated overnight at 4°C with primary antibodies
(all from Cell Signaling) PARP antibody (clone 46D11), survivin
antibody (clone 71G4B7), or GAPDH antibody (clone D16H11).
As a loading control, α-tubulin staining (clone DM1A;
Sigma-Aldrich, Zwijndrecht, the Netherlands) was included. After
incubation with the secondary HRP-conjugated antibody for 30
minutes at room temperature, membranes were treated with ECL2
substrate (Pierce, Thermo Scientific) as per manufacturer's
instructions, and chemiluminescence was captured using ECL
hyperfilm (Amersham, GE Healthcare Life Sciences, Eindhoven, the
Netherlands).
Cell Cycle Analysis
Cell lines were cultured in T25 flasks in amounts ensuring 70% to
90% confluency when harvested and treated with the YM155 IC50
concentrations. After 48-hour treatment, cells were prepared for flow
cytometric analysis. In short, cells were harvested, counted, and fixed
in ice-cold methanol. Next, cells were washed, treated with RNase,
and stained for DNA using propidium iodide and stored overnight at
4°C. Next day, cells were analyzed using an LSRII flowcytomer (BD
biosciences). A blue 488-nm, 20-mW laser was used for excitation.
Propidium iodide fluorescence was collected using a 610/20 band
pass filter. Data analysis was performed by using WinList 8 remotely
connected to ModFit LT 4 (Verity Software House, Topsham, ME)
[25]. Each data file contained at least 10,000 single cell events. A
one-compartment polynomial model was used for calculating the
percentage G1, S, and G2M phase of the cell cycle. This statistical
model showed the best fit.
Statistical Analysis
Dose-response curves and IC50 values were determined using
GraphPad Prism (version 6.05; GraphPad Software, La Jolla, CA).
Mann-Whitney testing was performed to investigate differences in
survivin expression (GraphPad Prism). Statistically significant
differences in cell cycle phases before and after treatment with
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using Tukey's multiple-comparisons testing.
Results
Identification of 27 Compounds Effective Against MLS Tumor
Cells
Two hundred seventy-three compounds were tested in three
MLS tumor cell lines. Twenty-seven drugs were shown to be effective,
which was defined as a loss of N50% cell viability in two or all three
cell lines at a drug concentration of 100 nM (Figure 1, Supplementary
Table 1). All three MLS cell lines showed a strong response (N80%
loss of cell viability) to treatment with the anthracyclines doxorubicin
and epirubicin at dose concentrations of both 100 nM and 1000 nM
(402-91 and 1765-92) and 1000 nM (DL-221) (Figure 1). The
tested taxanes, docetaxel and paclitaxel, as well as a member of
another class of mitotic inhibitors, vincristine, revealed a strong
decrease in cell viability at the lowest concentration of 1 nM (average
cell viabilities of the three cell lines, respectively, ~22%, ~24%, and
~19% after 72 hours of treatment). In the drug screen, YM155, a
survivin suppressant, showed in the 402-91 and 1765-92 cell line a
very strong decrease in cell viability (average ~13% cell viability) at allFigure 1. Hits of high throughput in vitro drug screen of three MLS ce
two or all three cell lines at a drug concentration of 100 nM. Strong inh
of three MLS cell lines. Also, a good response is observed to several c
paclitaxel. Per drug, four concentrations (1, 10, 100, and 1000 nM) are
red boxes to a loss of cell viability (~0%). For comparison, at the bo
criteria.four drug concentrations. In the DL-221 cell line, there was a
moderate reduction of the cell viability after treatment with YM155
at concentrations of 10, 100, and 1000 nM (ranging from 81% to
30% cell viability). Other interesting agents in the list are 17-DMAG
HCl, geldanamycin, SNX-5422, and SNX-2112, all targeting
HSP90. The list also contains around 15 drugs affecting the PI3K/
AKT/mTOR pathway, and although only omipalisib, gedatolisib,
and WYE-132 did meet the selection criteria of a reduction in cell
viability of more than 50% at 100 nM, also several other drugs
affecting the mTOR pathway demonstrated a response to treatment.
The response patterns of everolimus, temsirolimus, and sirolimus
were comparable, and they all showed a reduction in cell viability at
the lowest dose and almost no further reduction in cell viability at the
higher treatment concentrations (data not shown). The HDAC
inhibitors quisinostat, dacinostat, and panobinostat showed a strong
inhibitory effect in all three cell lines. KX2-391, an agent interfering
with the proto-oncogene Src, also was effective in all three cell lines.Validation of Selected Hits Using Cell Viability Assays
We selected the the survivin inhibitor YM155, the mTOR
inhibitor everolimus, and the broad-spectrum HDAC inhibitorll lines. List of 27 drugs with a reduction in cell viability of N50% in
ibitory effect of the survivin inhibitor YM155 is observed in two out
onventional chemotherapeutics, like doxorubicin, gemcitabine, and
tested; green boxes correspond to a high cell viability (~100%) and
ttom, five compounds are randomly shown that did not meet the
Figure 2. Role of survivin in MLS cell lines. Dose-response curves for YM155 (72 hours) in MLS cell lines. Error bars represents three
experiments performed in triplicates (A). Normalized RNA expression of three survivin isoforms in cell lines showing relative abundance of
the Δex3 isoform (B). Survivin immunohistochemistry of FFPE cell pellets revealed a strong nuclear survivin expression in the cell lines
402-91 (C), 1765-92 (D), and DL-221 (E) (20× magnification).
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assays. YM155 was of particular interest because this was the drug
with the best antitumor effect at the lowest treatment dose in two of
the three cell lines. The 402-91 and 1765-92 cell lines were
confirmed to be highly sensitive to YM155 and showed IC50 values of
6.3 nM and 5.1 nM, respectively (Figure 2A). The IC50 value of
DL-221 was 194 nM, which is consistent with the results observed in
the drug screen. In all three cell lines, an inhibition of cell viability
(~50%) was observed at a low dose concentration (~5 nM) of
everolimus (Supplementary Figure 1A). However, with increasing
dose, no further decrease of cell viability was observed. The tested cell
lines 402-91 and DL-221 demonstrated an IC50 value of 28 nM and
49 nM, respectively, after treatment with panobinostat (Supplemen-
tary Figure 1B).
To confirm the importance of BIRC5 in MLS cell survival, siRNA
experiments were performed. Knockdown of the survivin gene by
SMARTpool siBIRC5 resulted in a partial decrease of viability in all
three cell lines. Western blot analysis after transfection with siBIRC5
confirmed a decrease in survivin protein in all three cell lines with
variable knockdown efficiency (Supplementary Figure 2).
No Synergistic Effect of Everolimus or YM155 and
Trabectedin
As trabectedin (ET-743) is effective and therefore often used in the
treatment of MLS, we investigated possible synergy between
trabectedin and two of the validated screen hits, YM155 or
panobinostat. The MLS cell lines were confirmed to be sensitive to
trabectedin (Supplementary Figure 1C). Combination treatment oftrabectedin with YM155 showed no statistically significant difference
between the expected and the observed cell viability in all three tested
cell lines, indicating absence of synergism or antagonism for this drug
combination (Supplementary Figure 3, A, C, and E). The
combination of trabectedin and panobinostat was evaluated in the
402-91 and DL-221 cell lines, but again, no statistical significant
synergism or antagonism was observed (Supplementary Figure 3, B
and D).
Strong Nuclear Survivin Expression in All MLS Cell Lines and
Primary Tumors
Because YM155 was most efficient in decreasing MLS cell viability,
we evaluated the protein expression of survivin in the MLS cell lines.
The FFPE cell pellets of the three cell lines showed strong nuclear
survivin expression and a weak cytoplasmic expression in all three cell
lines (Figure 2, C-E). No difference in the expression levels was
observed.
Moreover, we examined the relative distribution of the three most
common survivin isoforms: survivin WT, survivin 2b, and survivin
Δex3, by quantitative reverse transcriptase PCR. All cell lines revealed
a similar mRNA expression pattern, with survivin Δex3 being most
highly expressed, followed by survivin WT, whereas the lowest
expression was found for survivin 2b (Figure 2B).
Next, we studied a cohort of MLS primary tumor samples. The
tumor samples of all 32 patients (100%) on the tissue microarrays
demonstrated strong nuclear expression of survivin protein (Figure 3A).
No statistically significant differences were observed between the
myxoid, intermediate, and round cell components (P N .05) (Figure 3,
Figure 3. High nuclear expression of survivin in MLS. Immunohistochemical analysis of nuclear survivin expression in 32 MLS patients
showing high expression in tumor components with myxoid, intermediate, and round cell morphology (A). High nuclear survivin
expression in tumor with myxoid morphology (B). High nuclear survivin expression in tumor with round cell morphology (C) (20×
magnification).
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single round cell liposarcoma with moderate cytoplasmic staining.
No Apoptosis But Increased S-Phase by YM155 in Two of
Three MLS Cell Lines
To further evaluate the mechanism of action of YM155 in MLS
cell lines, we evaluated PARP expression in all three MLS cell lines
using Western blot analysis, but no cleaved PARP was found in the
cell lines (Figure 4A) after 24 hours of YM155 treatment. Caspase 3/
7 activity after treatment with the survivin inhibitor YM155 at IC75Figure 4. Effect of YM155 on apoptosis and cell cycle. YM155 does no
the MLS cell lines. Western blot analysis for PARP and cleaved PARP e
lines treated with YM155 for 48 hours, measured in two independent
in G1 and an increase in S-phase after treatment. DL-221 does not shconcentration also revealed no significant increase in caspase 3/7
activity after 24 hours (data not shown). These results indicate that
YM155 does not induce apoptosis in MLS.
We subsequently performed cell cycle analysis to evaluate a
possible effect of YM155 on cell cycle regulation. After 48 hours,
YM155-treated cells revealed an increase in the S-phase fraction
and a decrease in the G1 fraction as compared with untreated
402-91 and 1765-92 cells. In DL-221, no clear changes were
observed in cell cycle distribution after YM155 treatment (Figure
4B).t cause PARP-dependent apoptosis but increases S-phase in two of
xpression in MLS cell lines (A). FACS cell cycle analysis of MLS cell
experiments. Two cell lines, 402-91 and 1765-92, show a decrease
ow a difference in cell cycle distribution (B).
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MLS initially often responds well to treatment with radiotherapy,
conventional chemotherapeutics, or trabectedin; however, after
several treatment cycles, the effect of treatment is observed to
decrease. Therefore, for patients with locally advanced or metastatic
disease, new therapeutic options are highly warranted to improve
survival. In this study, our aim was to identify novel candidate targets
for treatment by performing a high-throughput drug screen with
multiple targeted (tyrosine kinase) inhibitors as well as substances of
other classes.
The 27 most effective compounds (Figure 1) include the
conventional chemotherapeutic agents used in daily practice, such
as anthracyclines and taxanes, as anticipated. In addition, the results
included three potent inhibitors of the PI3K/AKT/mTOR pathway
(omipalisib, gedatolisib, and WYE-125132). A subset of MLSs
demonstrates dysregulation of this pathway by PIK3CA mutation,
loss of PTEN expression, or Akt activation [26–28]. No large series
on mTOR inhibition in MLS patients is available, although in two
cases, a minor response has been observed [29], and a clinical trial is
ongoing (COSYMO www.clinicaltrials.gov NCT02821507). In the
current study, we found a decrease of cell viability down to 50% at
low-dose treatment with everolimus. Unlike three other inhibitors of
the mTOR pathway, everolimus did not end up in the list of most
effective drugs of the drug screen, which is caused by the fact that, at
the higher drug concentrations, no reduction of cell viability above
50% was achieved. This suggests that, in clinical studies, the drug
may need to be combined with another (chemotherapeutic) drug.
Interestingly, BI2536, a potent PLK1 inhibitor, was also one of the
hits of the drug screen, and we confirm that inhibition of PLK1
results in a decrease in cell viability (Supplementary Figure 2A). As
PLK1 was very recently shown to interact with the mTOR pathway
by inhibiting MTORC1, it might be interesting to further explore
combination treatment in MLS [30]. Moreover, dual treatment of
temsirolimus with YM155 demonstrated an improved antitumor
effect in a renal cancer model [53].
The Src inhibitor KX2-391 is another interesting hit confirming
previous preclinical results, as two previous studies reported that the
Src pathway is highly active in MLS [31,32]. KX2-391 is the first
clinical Src inhibitor targeting the peptide substrate-binding site, with
higher in vitro potency than dasatinib [33]. In a small phase I study
with several solid malignancies, favorable pharmacokinetics and
antitumor activity were observed [34].
We demonstrate that inhibition of survivin by YM155 results in a
significant decrease of cell viability in two out of three cell lines
(402-91 and 1765-92), whereas DL-221 seems less dependent on
survivin. A similar trend was seen using siRNA for BIRC5 in DL221;
despite almost complete knockdown, the effect on viability is
comparable to 402-91, in which knockdown was ~50% (Supple-
mentary Figure 2). YM155 blocks BIRC5 at the promoter region. In
addition to this inhibition at the transcriptional level, also at the
posttranscriptional level, survivin can be downregulated by the
addition of CDK or HSP90 inhibitors which are known to interact
with the expression of BIRC5 in the cells [35]. Interestingly, 4 of the
27 hits emerging from the compound screen target HSP90 (Figure 1)
and demonstrate a strong inhibitory effect on cell viability. A recent
study also demonstrates an important role for HSP90 inhibitor
17-DMAG resulting in decreased phosphorylation of several receptor
tyrosine kinases and demonstrating massive tumor cell death in a
xenograft model [36].Survivin (BIRC5) is a member of the inhibitor of apoptosis
family and is a multifunctional protein that is involved in several
important cellular processes in both the nucleus and the
cytoplasm. Survivin interacts with aurora B kinase, and both are
part of the chromosomal passenger complex, which forms at the
kinetochore in the nucleus and regulates microtubule-kinetochore
attachment, ensuring proper segregation of the sister chromatids
during mitosis [37,38]. Cytoplasmic survivin is involved in two
processes. On one hand, it is involved in the binding of XIAP,
which inhibits caspase-9 and prevents activation of the apoptotic
pathway. In addition, survivin is able to activate AKT and to
upregulate α5 integrin, resulting in stimulation of cell motility.
Normally, survivin is expressed during fetal development and also
in certain differentiated tissues. High expression of survivin has
been found in several malignancies, including sarcomas such as
malignant peripheral nerve sheath tumor, pleomorphic liposar-
coma, uterine leiomyosarcoma, chondrosarcoma, and Ewing
sarcoma [20,39–43].
All primary MLS tumor samples, as well as the three cell lines,
showed high nuclear expression of survivin. There are multiple
survivin isoforms described. Several studies show a particular
overexpression of survivin Δex3 in several malignancies, includ-
ing, for example, breast and colon carcinoma and soft tissue
sarcomas [44,45]. The expression of this isoform is also
associated with a worse prognosis. We here show that, also in
the MLS cell lines, the survivin Δex3 isoform is relatively
abundant.
Previously, we and others showed that inhibition of survivin by
YM155 is effective in vitro in several other malignancies,
including squamous cell carcinoma, gastrointestinal stromal
tumor, and chondrosarcoma [20,46,47]. Evaluation of the effect
of YM155 in in vivo models for gastric carcinoma and
osteosarcoma demonstrated a suppression of tumor growth in
mice [48,49]. The mechanism of action of YM155 as anticancer
drug is still a matter of debate. Although initially proposed as a
BIRC5 transcriptional repressor, YM155 has been subsequently
shown to induce DNA damage [50] and to inhibit double-strand
break repair [51]. In most of the carcinoma models, survivin
inhibition induces apoptosis, whereas for MLS as well as for
chondrosarcoma [20], survivin expression was predominantly
nuclear. Based on its role in maintaining proper sister chromatid
segregation during mitosis, depletion of BIRC5 has indeed been
described to induce a prominent defect in mitosis without direct
induction of apoptosis [52]. This has led to the hypothesis that the
antiapoptotic function of BIRC5 is secondary to its role in mitosis.
Strikingly, after treatment with YM155, we observed an increase
in percentage of cells in S-phase in 402-91 and 1765-92. This
phenomenon has also been observed in other cancer models
[20,53] and may be interpreted in the context of “mitotic
catastrophe,” a type of cell death that occurs during mitosis and is
being controlled by numerous molecular players including
survivin [52]. However, a high S-phase is significantly associated
with a poor prognosis [54,55]. Furthermore, survivin knockdowns
by shRNA increased chromosomal instability, irrespective of p53
[56]. As, together with a high S-phase, this might lead to clonal
selection and outgrowth of resistant clones, this warrants further
investigation.
In conclusion, using a large compound screen, we identified 27
compounds that are effective in decreasing cell viability of MLS cells.
Translational Oncology Vol. 10, No. 4, 2017 Survivin as a target in myxoid liposarcoma de Graaff et al. 553We identified survivin as being essential for MLS tumor growth.
Survivin is expressed in 100% of tumor samples. Although the
S-phase increased, a strong decrease in cell viability was observed in
two of three tumor cell lines, which warrants further investigation for
possible treatment of advanced MLS patients with YM155 targeting
survivin.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2017.05.007.
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